Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
scientific article published on 4 September 2013
Author/s
author: Athanasios Dimopoulos, Ramón García-Sanz, Giovanni Palladini, Giampaolo Merlini, Efstathios Kastritis, Pieter Sonneveld, Eurydiki Michalis, Dimitra Gika, Maria Gavriatopoulou, Marie-Christine Kyrtsonis, Zafiris Kartasis, Alessandra Tedeschi
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.